Cabozantinib plus nivolumab showed a 71% response rate in FH-dRCC, extending efficacy beyond non-clear cell RCC. The study ...

Although late-stage kidney cancer generated poor survival rates for over two decades, significant progress is being made in the treatment of the disease. Although late-stage kidney cancer generated ...

Keytruda and Lenvima combination showed a 50.6% overall response rate and 82.3% disease control rate in advanced non-clear cell kidney cancer. The median progression-free survival was 17.9 months, ...

Clear cell renal cell carcinoma (ccRCC) is still a clinical challenge due to its high metastasis rate at diagnosis and therapy resistance. It accounts for about 75%-80% of RCC cases. The magnesium ...

(Reuters) - A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone ...

Study findings accounting for clinical selection bias support active surveillance of small renal masses in routine clinical practice. Active surveillance of small renal masses is as safe as partial ...

JACKSONVILLE, Fla. — Black people in the United States are at the highest risk for cancer death. According to the Centers for Disease Control, African Americans have a lower overall 5-year cancer ...

A majority of patients with non-locally treated brain metastases from kidney cancer remained free of metastatic progression for at least 6 months when treated with cabozantinib (Cabometyx), a small ...